Innovent Biologics ( (HK:1801) ) has provided an announcement.
Innovent Biologics has announced that its third-generation EGFR TKI, limertinib, has received approval from China’s National Medical Products Administration for first-line treatment of certain types of non-small cell lung cancer (NSCLC). This approval is based on positive results from a Phase 3 clinical trial, which demonstrated that limertinib significantly prolongs progression-free survival compared to gefitinib. The approval is expected to strengthen Innovent’s position in the oncology market and provide a new treatment option for patients with high-unmet needs.
More about Innovent Biologics
Innovent Biologics, Inc. is a biotechnology company focused on developing and commercializing high-quality biopharmaceuticals for the treatment of cancer. The company has built a robust portfolio of precision therapies, including limertinib, Retsevmo, Dupert, and DOVBLERON, aiming to enhance their synergistic value and reinforce its leadership position in oncology.
YTD Price Performance: 30.46%
Average Trading Volume: 12,165
Technical Sentiment Signal: Sell
Current Market Cap: $11.6B
Learn more about 1801 stock on TipRanks’ Stock Analysis page.